ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Immunology
インパクトファクター: 1.352 5年インパクトファクター: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472

巻:
巻 39, 2019 巻 38, 2018 巻 37, 2017 巻 36, 2016 巻 35, 2015 巻 34, 2014 巻 33, 2013 巻 32, 2012 巻 31, 2011 巻 30, 2010 巻 29, 2009 巻 28, 2008 巻 27, 2007 巻 26, 2006 巻 25, 2005 巻 24, 2004 巻 23, 2003 巻 22, 2002 巻 21, 2001 巻 20, 2000 巻 19, 1999 巻 18, 1998 巻 17, 1997 巻 16, 1996 巻 15, 1995 巻 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2015012558
pages 49-57

Interleukin 35−Producing B Cells (i35-Breg): A New Mediator of Regulatory B-Cell Functions in CNS Autoimmune Diseases

Charles E. Egwuagu
Molecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), National Institutes of Health (NIH), Bethesda, Maryland 20892
Cheng-Rong Yu
Molecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), National Institutes of Health (NIH), Bethesda, Maryland 20892

要約

Neuroinflammation contributes to neuronal deficits in neurodegenerative CNS (central nervous system) autoimmune diseases, such as multiple sclerosis and uveitis. The major goal of most treatment modalities for CNS autoimmune diseases is to limit inflammatory responses in the CNS; immune-suppressive drugs are the therapy of choice. However, lifelong immunosuppression increases the occurrence of infections, nephrotoxicity, malignancies, cataractogenesis, and glaucoma, which can greatly impair quality of life for the patient. Biologics that target pathogenic T cells is an alternative approach that is gaining wide acceptance as indicated by the popularity of a variety of Food and Drug Administration (FDA)-approved anti-inflammatory compounds and humanized antibodies such as Zenapax, Etanercept, Remicade, anti-ICAM, rapamycin, or tacrolimus. B cells are also potential therapeutic targets because they provide costimulatory signals that activate pathogenic T cells and secrete cytokines that promote autoimmune pathology. B cells also produce autoreactive antibodies implicated in several organ-specific and systemic autoimmune diseases including lupus erythematosus, Graves' disease, and Hashimoto's thyroiditis. On the other hand, recent studies have led to the discovery of several regulatory B-cell (Breg) populations that suppress immune responses and autoimmune diseases. In this review, we present a brief overview of Breg phenotypes and in particular, the newly discovered IL35-producing regulatory B cell (i35-Breg). We discuss the critical roles played by i35-Bregs in regulating autoimmune diseases and the potential use of adoptive Breg therapy in CNS autoimmune diseases.


Articles with similar content:

T Regulatory Cells: A Promising New Target in Atherosclerosis
Critical Reviews™ in Immunology, Vol.34, 2014, issue 5
loannis Gkougkourelas , Panagiota Boura, Konstantinos Tselios, Alexandros Sarantopoulos
Glucocorticoid-Induced Apoptosis in Animal Models of Multiple Sclerosis
Critical Reviews™ in Immunology, Vol.33, 2013, issue 3
Marco J. Herold, Holger Reichardt
Immunotherapeutic Approaches to Head and Neck Cancer
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 3-4
Hassan Nasser, Maie St. John
Natural IgM and the Development of B Cell-Mediated Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.36, 2016, issue 2
Nicole Baumgarth, Trang T. T. Nguyen
Immunotherapeutic Approaches for Glioma
Critical Reviews™ in Immunology, Vol.29, 2009, issue 1
Xinmei Zhu, Gary Kohanbash, Mitsugu Fujita, Aki Hoji, Ryo Ueda, Edward R. Kastenhuber, Hideho Okada